Burkitt Lymphoma: all 407 studies
Page 1 of 5. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.
- CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II StudyNot yet recruitingNCT07890025Phase 1/2
- Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.Not yet recruitingNCT07883941Phase 1
- BLinatumomab and iNKT in Relapsed B-Cell ALLNot yet recruitingNCT07869368Phase 1
- Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaRecruitingNCT07862010Early Phase 1
- Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic LeukemiaRecruitingNCT07838714Phase 1
- SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07830238Early Phase 1
- Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic SyndromeNot yet recruitingNCT07819396Phase 2
- A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07770698Phase 1/2
- Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic LymphomaNot yet recruitingNCT07758673Phase 1
- Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell LymphomaNot yet recruitingNCT07754682Phase 3
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaNot yet recruitingNCT07724457Phase 2/3
- Study Of KITE-753 in R/R B-Cell ALLNot yet recruitingNCT07674823Phase 1
- Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK StudyNot yet recruitingNCT07662928Phase 2
- Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesRecruitingNCT07648264Phase 3
- Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07637929
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingNCT07636564Phase 2
- CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic LeukemiaNot yet recruitingNCT07623655
- Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic LeukemiaRecruitingNCT07575971Phase 1/2
- Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALLRecruitingNCT07575919Phase 1/2
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)RecruitingNCT07570173Phase 2/3
- Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07564453Phase 2
- Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic TumorsNot yet recruitingNCT07539610Phase 1
- Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaRecruitingNCT07532525Phase 1
- Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Phase 1/2
- NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)RecruitingNCT07502118Phase 2/3
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)Not yet recruitingNCT07476729Phase 3
- Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaRecruitingNCT07429461Early Phase 1
- A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received BlinatumomabRecruitingNCT07422337
- This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including RNot yet recruitingNCT07412405Not applicable
- A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07313852Phase 1/2
- Autologous Bedside CD19 CAR T-cell Therapy for B-ALLNot yet recruitingNCT07277504Early Phase 1
- Allogeneic UCB-derived CAR-T for B-ALLNot yet recruitingNCT07256353Early Phase 1
- In VIVO CAR-T Therapy for Relapsed/Refractory Hematological MalignanciesRecruitingNCT07239323Phase 1
- A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell NeoplasmsNot yet recruitingNCT07234045Phase 1
- A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07223021Phase 3
- A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic AnemiaRecruitingNCT07205315Early Phase 1
- Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell LymphomaNot yet recruitingNCT07168291Early Phase 1
- Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07133997Phase 1
- Blinatumomab Consolidation in Real WorldRecruitingNCT07117136
- RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic MalignanciesNot yet recruitingNCT07113496Phase 1
- Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic LeukemiaRecruitingNCT07109219Phase 1/2
- CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesRecruitingNCT07106749Phase 1
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingNCT07097363Phase 2
- Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)RecruitingNCT07078929Phase 1
- Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneRecruitingNCT07069699Phase 1/2
- CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse ReactionsRecruitingNCT07048535
- A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07043218Phase 1
- A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.RecruitingNCT06927466Phase 1
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingNCT06918431Phase 2
- Gut Health in Children With CancerRecruitingNCT06899581
- Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Phase 2/3
- Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell MalignanciesRecruitingNCT06879340Phase 1
- Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALLRecruitingNCT06863259Phase 1
- Expanded Access Program for OOS Obe-celAvailableNCT06799221
- Immunotherapy in LymphomaRecruitingNCT06796517
- Long-term Follow up Local Registry Study of Kymriah in South KoreaRecruitingNCT06785818
- CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic LeukemiaRecruitingNCT06777979Phase 1
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Phase 2/3
- Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/LeukemiaRecruitingNCT06710418Not applicable
- Study of YK012 in B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06580301Phase 1/2
- CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALLRecruitingNCT06559189Phase 1
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)RecruitingNCT06533579Phase 1/2
- JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT06514768Early Phase 1
- Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALLRecruitingNCT06507514Phase 1
- Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)RecruitingNCT06395103Phase 1/2
- CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell DysfunctionRecruitingNCT06389305Not applicable
- Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL PatientsRecruitingNCT06343090Not applicable
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasRecruitingNCT06340737Phase 1
- Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical TrialRecruitingNCT06326008Phase 1
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingNCT06317662Phase 2
- Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabRecruitingNCT06287229Phase 1/2
- CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT06208735Phase 1
- A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)RecruitingNCT06173518Phase 1
- Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT06144606Phase 2
- AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaRecruitingNCT06137118Phase 1/2
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT06124157Phase 2
- Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALLRecruitingNCT06080191Phase 1
- Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineRecruitingNCT06060782Phase 1
- LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesRecruitingNCT05990465Phase 1
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingRecruitingNCT05794880Not applicable
- Co-administration of CART22-65s and huCART19 for B-ALLRecruitingNCT05674175Phase 1/2
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)RecruitingNCT05667506Phase 1/2
- Study of SGR-1505 in Mature B-Cell NeoplasmsRecruitingNCT05544019Phase 1
- B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021RecruitingNCT05518383Phase 4
- Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)RecruitingNCT05480449Phase 1/2
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesRecruitingNCT05442515Phase 1/2
- Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesRecruitingNCT05418088Phase 1
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 1
- Caloric Restriction and Activity to Reduce Chemoresistance in B-ALLRecruitingNCT05082519Phase 2
- Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell LymphomaRecruitingNCT05020392Phase 3
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT04546399Phase 2
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaRecruitingNCT04545762Phase 1
- UCD19 CarT in Treatment of Pediatric B-ALL and B-NHLRecruitingNCT04544592Phase 1/2
- Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaRecruitingNCT04491370Phase 1/2
- Recommendations for the Treatment of Children With Burkitt's LymphomaRecruitingNCT04425421
- Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLRecruitingNCT04260022Phase 1
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2
- Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)RecruitingNCT04150497Phase 1/2